Ziopharm Ocology Inc (NASDAQ:ZIOP) has rebranded itself and has changed its name to Alaunos Therapeutics Inc.
- The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow.
- Along with the name change, the Company amended Phase 1/2 IND to add four additional T-cell receptors (TCRs) to its library, increasing the number of eligible patients for the clinical trial.
- Related: Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%.
- Phase 1/2 TCR-T library trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications is open for enrollment at Texas' MD Anderson Cancer Center.
- Dosing is expected to start in 1H of 2022.
- Additionally, to streamline operations, the Company has closed its Boston office. Alaunos will be headquartered in Houston.
- Price Action: ZIOP shares are up 1.02% at $0.88 during the market session on the last check Wednesday.
